Senti Biosciences (SNTI) Competitors $2.16 +0.04 (+1.89%) (As of 01:24 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SNTI vs. ANEB, BRNS, OSTX, CVM, LUMO, CERO, RAPT, OKYO, NXTC, and ELEVShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include Anebulo Pharmaceuticals (ANEB), Barinthus Biotherapeutics (BRNS), OS Therapies (OSTX), CEL-SCI (CVM), Lumos Pharma (LUMO), CERo Therapeutics (CERO), RAPT Therapeutics (RAPT), OKYO Pharma (OKYO), NextCure (NXTC), and Elevation Oncology (ELEV). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Anebulo Pharmaceuticals Barinthus Biotherapeutics OS Therapies CEL-SCI Lumos Pharma CERo Therapeutics RAPT Therapeutics OKYO Pharma NextCure Elevation Oncology Senti Biosciences (NASDAQ:SNTI) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends. Do insiders & institutionals have more ownership in SNTI or ANEB? 25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 15.9% of Senti Biosciences shares are owned by insiders. Comparatively, 85.9% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation & earnings, SNTI or ANEB? Anebulo Pharmaceuticals has lower revenue, but higher earnings than Senti Biosciences. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSenti Biosciences$2.56M3.87-$71.06M-$15.56-0.14Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.30-5.03 Does the media prefer SNTI or ANEB? In the previous week, Anebulo Pharmaceuticals had 3 more articles in the media than Senti Biosciences. MarketBeat recorded 5 mentions for Anebulo Pharmaceuticals and 2 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 0.72 beat Anebulo Pharmaceuticals' score of -0.36 indicating that Senti Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Senti Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anebulo Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, SNTI or ANEB? Senti Biosciences has a beta of 2.74, suggesting that its share price is 174% more volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1, suggesting that its share price is 200% less volatile than the S&P 500. Does the MarketBeat Community prefer SNTI or ANEB? Anebulo Pharmaceuticals received 6 more outperform votes than Senti Biosciences when rated by MarketBeat users. Likewise, 90.00% of users gave Anebulo Pharmaceuticals an outperform vote while only 33.33% of users gave Senti Biosciences an outperform vote. CompanyUnderperformOutperformSenti BiosciencesOutperform Votes333.33% Underperform Votes666.67% Anebulo PharmaceuticalsOutperform Votes990.00% Underperform Votes110.00% Is SNTI or ANEB more profitable? Senti Biosciences' return on equity of -154.84% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Senti BiosciencesN/A -154.84% -77.42% Anebulo Pharmaceuticals N/A -184.40%-158.14% Do analysts prefer SNTI or ANEB? Anebulo Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 429.80%. Given Anebulo Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Anebulo Pharmaceuticals is more favorable than Senti Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAnebulo Pharmaceuticals beats Senti Biosciences on 10 of the 16 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.91M$2.97B$5.10B$8.84BDividend YieldN/A1.91%5.04%4.07%P/E Ratio-0.1419.5495.6214.26Price / Sales3.87283.311,217.1987.73Price / CashN/A169.3839.5936.27Price / Book0.624.356.946.36Net Income-$71.06M-$41.63M$118.89M$225.56M7 Day Performance-7.30%-4.44%-1.33%-0.10%1 Month Performance-4.42%-6.01%-3.17%2.02%1 Year Performance-41.21%26.52%32.49%27.87% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences1.0644 of 5 stars$2.16+1.9%N/A-42.1%$9.91M$2.56M-0.144News CoverageANEBAnebulo Pharmaceuticals2.5152 of 5 stars$1.51-0.7%$8.00+429.8%-30.9%$39.15MN/A0.004Analyst ForecastShort Interest ↓News CoverageGap DownHigh Trading VolumeBRNSBarinthus Biotherapeutics1.6614 of 5 stars$0.99+10.1%$5.83+489.3%-69.1%$39.14M$800,000.00-0.60107Analyst ForecastOSTXOS TherapiesN/A$1.83+6.1%N/AN/A$38.87MN/A0.00N/ACVMCEL-SCIN/A$0.60-3.7%N/A-74.0%$38.59MN/A0.0043Analyst DowngradeLUMOLumos Pharma3.2177 of 5 stars$4.33+0.2%$8.63+99.2%+41.2%$37.45M$2.05M0.0030High Trading VolumeCEROCERo TherapeuticsN/A$0.25-0.7%N/AN/A$37.13MN/A0.008Gap DownRAPTRAPT Therapeutics4.5983 of 5 stars$1.06-1.4%$9.50+800.5%-92.3%$36.88M$1.53M0.0080OKYOOKYO Pharma2.1572 of 5 stars$1.07flat$7.00+554.2%-38.2%$36.21MN/A0.007NXTCNextCure4.4003 of 5 stars$1.28-1.5%$4.00+212.3%+4.8%$35.88MN/A-0.6290ELEVElevation Oncology2.0229 of 5 stars$0.60+3.8%$7.80+1,192.9%+24.0%$35.67MN/A0.0040Gap Up Related Companies and Tools Related Companies Anebulo Pharmaceuticals Alternatives Barinthus Biotherapeutics Alternatives OS Therapies Alternatives CEL-SCI Alternatives Lumos Pharma Alternatives CERo Therapeutics Alternatives RAPT Therapeutics Alternatives OKYO Pharma Alternatives NextCure Alternatives Elevation Oncology Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNTI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNTI Stock Alerts